Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 9-10/2016

01.06.2016 | themenschwerpunkt

Medikamentöse Behandlung chronischer Venenerkrankungen

verfasst von: Miloš D. Pavlović

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Chronische Venenerkrankungen (CVE) betreffen zumindest 15–25 % der Allgemeinbevölkerung und sind nicht nur mit hoher Morbidität, sondern auch mit beträchtlichen finanziellen Belastungen verbunden. Die moderne CVE-Behandlung stützt sich vor allem auf endovenöse therapeutische Verfahren und Kompressionstherapie. Je mehr Einblicke wir allmählich in die Pathogenese der CVE gewinnen, desto mehr steigt auch das Interesse an Arzneimitteln, die diesen Prozess beeinflussen können. Nachfolgend finden Sie einen Überblick über die meisten oralen Präparate, die derzeit zur Behandlung von CVE (einschließlich venöser Beingeschwüre) eingesetzt werden. Nach mehreren Jahrzehnten klinischer Verwendung liegen für einige Flavonoidpräparate, in erster Linie für MPFF (mikronisierte gereinigte Flavonoidfraktion), genügend Nachweise vor, um sie als kurzfristige Zusatzbehandlung bei CVE empfehlen zu können. Andere Verbindungen sind jedoch diesbezüglich ebenfalls äußerst vielversprechend. Dennoch benötigen wir mehr umfassendere klinische Studien über einen längeren Zeitraum hinweg, um Wirkung, Kosteneffizienz und vor allem eine mögliche prophylaktische Anwendung dieser Medikamente genauer definieren zu können. Mehr über die Grundlagen von CVE zu erfahren hilft uns bei der Entwicklung neuer Arzneimittel, die auf spezielle Aspekte des Erkrankungsprozesses ausgerichtet sind.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41:117–25. CrossRefPubMed Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41:117–25. CrossRefPubMed
2.
Zurück zum Zitat Anwar MA, Georgiadis KA, Shalhoub J, et al. A review of familial, genetic, and congenital aspects of primary varicose vein disease. Circ Cardiovasc Genet. 2012;5:460–6. CrossRefPubMed Anwar MA, Georgiadis KA, Shalhoub J, et al. A review of familial, genetic, and congenital aspects of primary varicose vein disease. Circ Cardiovasc Genet. 2012;5:460–6. CrossRefPubMed
3.
4.
Zurück zum Zitat Brunner F, Hoffmann C, Schuller-Petrović S. Responsiveness of human varicose saphenous veins to vasoactive agents. Br J Clin Pharmacol. 2001;51:219–24. CrossRefPubMedPubMedCentral Brunner F, Hoffmann C, Schuller-Petrović S. Responsiveness of human varicose saphenous veins to vasoactive agents. Br J Clin Pharmacol. 2001;51:219–24. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Rabe E, Guex JJ, Morrison N, et al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013;28:308–19. CrossRefPubMed Rabe E, Guex JJ, Morrison N, et al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. Phlebology. 2013;28:308–19. CrossRefPubMed
6.
Zurück zum Zitat Farinola N, Piller N. Pharmacogenomics – its role in re-establishing coumarin as treatment for lymphedema. Lymphat Res Biol. 2005;3:81–6. CrossRefPubMed Farinola N, Piller N. Pharmacogenomics – its role in re-establishing coumarin as treatment for lymphedema. Lymphat Res Biol. 2005;3:81–6. CrossRefPubMed
7.
Zurück zum Zitat Hadjipavlou-Litina D, Kontogiorgis C, Pontiki E, et al. Anti-inflammatory and antioxidant activity of coumarins designed as potential fluorescent zinc sensors. J Enzyme Inhib Med Chem. 2007;22:287–92. CrossRefPubMed Hadjipavlou-Litina D, Kontogiorgis C, Pontiki E, et al. Anti-inflammatory and antioxidant activity of coumarins designed as potential fluorescent zinc sensors. J Enzyme Inhib Med Chem. 2007;22:287–92. CrossRefPubMed
8.
Zurück zum Zitat Cardoso SH, Barreto MB, Lourenco MC, et al. Antitubercular activity of new coumarins. Chem Biol Drug Des. 2011;77:489–93. CrossRefPubMed Cardoso SH, Barreto MB, Lourenco MC, et al. Antitubercular activity of new coumarins. Chem Biol Drug Des. 2011;77:489–93. CrossRefPubMed
9.
Zurück zum Zitat Lee S, Sivakumar K, Shin WS, et al. Synthesis and antiangiogenesis activity of coumarin derivatives. Bioor Med Chem Lett. 2006;16:4596–9. CrossRef Lee S, Sivakumar K, Shin WS, et al. Synthesis and antiangiogenesis activity of coumarin derivatives. Bioor Med Chem Lett. 2006;16:4596–9. CrossRef
10.
Zurück zum Zitat Gupta S, Singh S, Kathuria A, et al. Ammonium derivatives of chromenones and quinolinones as lead antimicrobial agents. J Chem Sci. 2012;124:437–49. CrossRef Gupta S, Singh S, Kathuria A, et al. Ammonium derivatives of chromenones and quinolinones as lead antimicrobial agents. J Chem Sci. 2012;124:437–49. CrossRef
11.
Zurück zum Zitat Lin MH, Cheng CH, Chen KC, et al. Induction of ROS-independent JNK-activation-mediated apoptosis by a novel coumarin-derivative, DMAC, in human colon cancer cells. Chem Biol Interact. 2014;218:42–9. CrossRefPubMed Lin MH, Cheng CH, Chen KC, et al. Induction of ROS-independent JNK-activation-mediated apoptosis by a novel coumarin-derivative, DMAC, in human colon cancer cells. Chem Biol Interact. 2014;218:42–9. CrossRefPubMed
12.
Zurück zum Zitat Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med. 1993;329:1158–63. CrossRefPubMed Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med. 1993;329:1158–63. CrossRefPubMed
13.
Zurück zum Zitat Casley-Smith JR, Wang CT, Casley-Smith JR, et al. Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin). BMJ. 1993;307:1037–41. CrossRefPubMedPubMedCentral Casley-Smith JR, Wang CT, Casley-Smith JR, et al. Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin). BMJ. 1993;307:1037–41. CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa. 2002;31:185–90. CrossRefPubMed Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa. 2002;31:185–90. CrossRefPubMed
15.
Zurück zum Zitat Badger C, Preston N, Seers K, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;2:CD003140. PubMed Badger C, Preston N, Seers K, et al. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;2:CD003140. PubMed
16.
Zurück zum Zitat Kinonen T, Pasanen M, Gynther J, et al. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouseCYP 2A5 and human CYP 2A6. Br J Pharmacol. 1995;116:2625–30. CrossRefPubMedPubMedCentral Kinonen T, Pasanen M, Gynther J, et al. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouseCYP 2A5 and human CYP 2A6. Br J Pharmacol. 1995;116:2625–30. CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Chinembiri TN, du Plessis LH, Gerber M, et al. Review of Natural Compounds for Potential Skin Cancer Treatment. Molecules. 2014;19:11679–721. CrossRefPubMed Chinembiri TN, du Plessis LH, Gerber M, et al. Review of Natural Compounds for Potential Skin Cancer Treatment. Molecules. 2014;19:11679–721. CrossRefPubMed
18.
Zurück zum Zitat Raffetto JD, Khalil RA. Ca2+-dependent contraction by the saponoside escin in rat vena cava: Implications in venotonic treatment of varicose veins . J Vasc Surg. 2011;54:489–96. CrossRefPubMedPubMedCentral Raffetto JD, Khalil RA. Ca2+-dependent contraction by the saponoside escin in rat vena cava: Implications in venotonic treatment of varicose veins . J Vasc Surg. 2011;54:489–96. CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lim CS, Kiriakidis S, Paleolog EM, et al. The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent. J Vasc Surg. 2012;56:1069–77. CrossRefPubMed Lim CS, Kiriakidis S, Paleolog EM, et al. The effects of doxycycline and micronized purified flavonoid fraction on human vein wall remodeling are not hypoxia-inducible factor pathway-dependent. J Vasc Surg. 2012;56:1069–77. CrossRefPubMed
20.
Zurück zum Zitat Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31:310–5. PubMed Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31:310–5. PubMed
21.
Zurück zum Zitat Scallon C, Bell-Syer SE, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev. 2013;31(5):CD006477 doi:10.1002/14651858.CD006477.pub2. Scallon C, Bell-Syer SE, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev. 2013;31(5):CD006477 doi:10.1002/14651858.CD006477.pub2.
22.
Zurück zum Zitat Ippolito E, Belcaro G, Dugall M, et al. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. Panminerva Med 2011; 53(3 Suppl 1): 13–9. Ippolito E, Belcaro G, Dugall M, et al. Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. Panminerva Med 2011; 53(3 Suppl 1): 13–9.
23.
Zurück zum Zitat Gulati, OP. Pycnogenol® in chronic venous insufficiency and related venous disorders. Phytother Res. 2014;28:348–62. CrossRefPubMed Gulati, OP. Pycnogenol® in chronic venous insufficiency and related venous disorders. Phytother Res. 2014;28:348–62. CrossRefPubMed
24.
Zurück zum Zitat Schoonees A, Visser J, Musekiwa A, et al. Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database Syst Rev. 2012;18(4):CD008294 doi:10.1002/14651858.CD008294.pub4. Schoonees A, Visser J, Musekiwa A, et al. Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database Syst Rev. 2012;18(4):CD008294 doi:10.1002/14651858.CD008294.pub4.
25.
Zurück zum Zitat Felixsson E, Persson IA, Eriksson AC, et al. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5‑HT(2A) receptors: an in vitro study. Phytother Res. 2010;24:1297–301. CrossRefPubMed Felixsson E, Persson IA, Eriksson AC, et al. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5‑HT(2A) receptors: an in vitro study. Phytother Res. 2010;24:1297–301. CrossRefPubMed
26.
Zurück zum Zitat Luís A, Domingues F, Duarte AP. Bioactive compounds, RP-HPLC analysis of phenolics, and antioxidant activity of some Portuguese shrub species extracts. Nat Prod Commun. 2011;6:1863–72. PubMed Luís A, Domingues F, Duarte AP. Bioactive compounds, RP-HPLC analysis of phenolics, and antioxidant activity of some Portuguese shrub species extracts. Nat Prod Commun. 2011;6:1863–72. PubMed
27.
Zurück zum Zitat Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012;14(11):CD003230 doi:10.1002/14651858.CD003230.pub4. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev. 2012;14(11):CD003230 doi:10.1002/14651858.CD003230.pub4.
28.
Zurück zum Zitat Cesarone MR, Incandela L, De Sanctis MT, et al. Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001;52(Suppl 2):S33–7. PubMed Cesarone MR, Incandela L, De Sanctis MT, et al. Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001;52(Suppl 2):S33–7. PubMed
29.
Zurück zum Zitat Arpaia MR, Ferrone R, Amitrano M, et al. Effects of Centella asiatica extract on mucopolysaccharide metabolism in subjects with varicose veins. Int J Clin Pharmacol Res. 1990;10:229–33. PubMed Arpaia MR, Ferrone R, Amitrano M, et al. Effects of Centella asiatica extract on mucopolysaccharide metabolism in subjects with varicose veins. Int J Clin Pharmacol Res. 1990;10:229–33. PubMed
30.
Zurück zum Zitat Janssens D, Michiels C, Guillaume G, et al. Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol. 1999;33:7–11. CrossRefPubMed Janssens D, Michiels C, Guillaume G, et al. Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. J Cardiovasc Pharmacol. 1999;33:7–11. CrossRefPubMed
31.
Zurück zum Zitat Arnould T, Michiels C, Janssens D, et al. Effect of Ginkor Fort on hypoxia-induced neutrophil adherence to human saphenous vein endothelium. J Cardiovasc Pharmacol. 1998;31:456–63. CrossRefPubMed Arnould T, Michiels C, Janssens D, et al. Effect of Ginkor Fort on hypoxia-induced neutrophil adherence to human saphenous vein endothelium. J Cardiovasc Pharmacol. 1998;31:456–63. CrossRefPubMed
32.
Zurück zum Zitat Romero-Cerecero O, Zamilpa-Álvarez A, Jiménez-Ferrer E, et al. Exploratory study on the effectiveness of a standardized extract from Ageratina pichinchensis in patients with chronic venous leg ulcers. Planta Med. 2012;78:304–10. CrossRefPubMed Romero-Cerecero O, Zamilpa-Álvarez A, Jiménez-Ferrer E, et al. Exploratory study on the effectiveness of a standardized extract from Ageratina pichinchensis in patients with chronic venous leg ulcers. Planta Med. 2012;78:304–10. CrossRefPubMed
33.
Zurück zum Zitat Gohel MS, Davies AH. Pharmacological treatment in patients with C 4, C 5 and C 6 venous disease. Phlebology. 2010;25(Suppl 1):35–41. CrossRefPubMed Gohel MS, Davies AH. Pharmacological treatment in patients with C 4, C 5 and C 6 venous disease. Phlebology. 2010;25(Suppl 1):35–41. CrossRefPubMed
34.
Zurück zum Zitat Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998;31:357–60. CrossRefPubMed Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol. 1998;31:357–60. CrossRefPubMed
35.
Zurück zum Zitat Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997;122:1502–8. CrossRefPubMedPubMedCentral Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol. 1997;122:1502–8. CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Piller NB. The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology. 1988;21:124–7. PubMed Piller NB. The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology. 1988;21:124–7. PubMed
37.
Zurück zum Zitat Angulo J, Peiró C, Romacho T, Fernández A, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol. 2011;667:153–9. CrossRefPubMed Angulo J, Peiró C, Romacho T, Fernández A, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol. 2011;667:153–9. CrossRefPubMed
38.
Zurück zum Zitat Alda O, Valero MS, Pereboom D, et al. In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins. Phlebology. 2011;26:332–7. CrossRefPubMed Alda O, Valero MS, Pereboom D, et al. In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins. Phlebology. 2011;26:332–7. CrossRefPubMed
39.
Zurück zum Zitat Iriz E, Vural C, Ereren E, et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa. 2008;37:233–40. CrossRefPubMed Iriz E, Vural C, Ereren E, et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa. 2008;37:233–40. CrossRefPubMed
40.
Zurück zum Zitat Martínez-Zapata MJ, Moreno RM, Gich I, et al. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatmentof chronic venous disease. Eur J Vasc Endovasc Surg. 2008;35:358–65. CrossRefPubMed Martínez-Zapata MJ, Moreno RM, Gich I, et al. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatmentof chronic venous disease. Eur J Vasc Endovasc Surg. 2008;35:358–65. CrossRefPubMed
41.
Zurück zum Zitat Rabe E, Jaeger KA, Bulitta M, et al. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011;26:162–8. CrossRefPubMed Rabe E, Jaeger KA, Bulitta M, et al. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011;26:162–8. CrossRefPubMed
42.
Zurück zum Zitat Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology. 2010;25:66–71. CrossRefPubMed Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology. 2010;25:66–71. CrossRefPubMed
43.
Zurück zum Zitat Ibáñez L, Vidal X, Ballarín E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869–74. CrossRefPubMed Ibáñez L, Vidal X, Ballarín E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869–74. CrossRefPubMed
44.
Zurück zum Zitat Raetsch C, Jia JD, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50:241–7. CrossRefPubMedPubMedCentral Raetsch C, Jia JD, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50:241–7. CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Bahra PS, Rainger GE, Wautier JL, et al. Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct. 2001;19:249–57. CrossRefPubMed Bahra PS, Rainger GE, Wautier JL, et al. Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct. 2001;19:249–57. CrossRefPubMed
46.
Zurück zum Zitat Maessen-Visch MB, de Roos KP. Dutch Venous Ulcer guideline update. Phlebology 2014; 29(1 suppl): 153–156. Maessen-Visch MB, de Roos KP. Dutch Venous Ulcer guideline update. Phlebology 2014; 29(1 suppl): 153–156.
47.
Zurück zum Zitat Jull AB, Arroll B, Parag V, et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012;12(12):CD001733 doi:10.1002/14651858.CD001733.pub3. PubMed Jull AB, Arroll B, Parag V, et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012;12(12):CD001733 doi:10.1002/14651858.CD001733.pub3. PubMed
48.
Zurück zum Zitat Babany G, Larrey D, Pessayre D, et al. Chronic active hepatitis caused by benzarone. J Hepatol. 1987;5:332–5. CrossRefPubMed Babany G, Larrey D, Pessayre D, et al. Chronic active hepatitis caused by benzarone. J Hepatol. 1987;5:332–5. CrossRefPubMed
49.
Zurück zum Zitat Hautekeete ML, Henrion J, Naegels S, et al. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver. 1995;15:25–9. CrossRefPubMed Hautekeete ML, Henrion J, Naegels S, et al. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver. 1995;15:25–9. CrossRefPubMed
50.
Zurück zum Zitat Winand R. Beta-naphthoquinone mono-semicarbarzone-2 (DCI naftazone) in varicose disease [in French. Rev Med Liege. 1977;32:429–31. PubMed Winand R. Beta-naphthoquinone mono-semicarbarzone-2 (DCI naftazone) in varicose disease [in French. Rev Med Liege. 1977;32:429–31. PubMed
51.
Zurück zum Zitat Klein-Soyer C, Bloy C, Archipoff G, et al. Naftazone accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hematol. 1995;37:187–92. PubMed Klein-Soyer C, Bloy C, Archipoff G, et al. Naftazone accelerates human saphenous vein endothelial cell proliferation in vitro. Nouv Rev Fr Hematol. 1995;37:187–92. PubMed
52.
Zurück zum Zitat Agha AM, Gad MZ. Lipid peroxidation and lysosomal integrity in different inflammatory models in rats: the effects of indomethacin and naftazone. Pharmacol Res. 1995;32:279–85. CrossRefPubMed Agha AM, Gad MZ. Lipid peroxidation and lysosomal integrity in different inflammatory models in rats: the effects of indomethacin and naftazone. Pharmacol Res. 1995;32:279–85. CrossRefPubMed
53.
Zurück zum Zitat Sogni P, Yang S, Pilette C, et al. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats. Eur J Pharmacol. 1998;344:37–43. CrossRefPubMed Sogni P, Yang S, Pilette C, et al. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats. Eur J Pharmacol. 1998;344:37–43. CrossRefPubMed
54.
Zurück zum Zitat McGregor L, Chignier E, Bloy C, et al. Effect of naftazone on in vivo platelet function in the rat. Platelets. 1999;10:66–70. CrossRefPubMed McGregor L, Chignier E, Bloy C, et al. Effect of naftazone on in vivo platelet function in the rat. Platelets. 1999;10:66–70. CrossRefPubMed
55.
Zurück zum Zitat Durand P, Bloy C, Peltier-Pujol F, et al. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone. J Pharm Pharmacol. 1996;48:566–72. CrossRefPubMed Durand P, Bloy C, Peltier-Pujol F, et al. In-vitro and ex-vivo inhibition of blood platelet aggregation by naftazone. J Pharm Pharmacol. 1996;48:566–72. CrossRefPubMed
56.
Zurück zum Zitat Rascol O, Ferreira J, Nègre-Pages L, et al. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease. Fundam Clin Pharmacol. 2012;26:557–64. CrossRefPubMed Rascol O, Ferreira J, Nègre-Pages L, et al. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease. Fundam Clin Pharmacol. 2012;26:557–64. CrossRefPubMed
57.
Zurück zum Zitat Pereira de Godoy JM. Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology. 2008;23:118–9. CrossRefPubMed Pereira de Godoy JM. Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology. 2008;23:118–9. CrossRefPubMed
58.
Zurück zum Zitat Scorza R, Santaniello A, Salazar G, et al. Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. Clin Ther. 2008;30:924–9. CrossRefPubMed Scorza R, Santaniello A, Salazar G, et al. Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. Clin Ther. 2008;30:924–9. CrossRefPubMed
59.
Zurück zum Zitat Scorza R, Santaniello A, Salazar G, et al. Aminaftone, a derivative of 4‑aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R D. 2008;9:251–7. CrossRefPubMed Scorza R, Santaniello A, Salazar G, et al. Aminaftone, a derivative of 4‑aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R D. 2008;9:251–7. CrossRefPubMed
60.
Zurück zum Zitat De Anna D, Mari F, Intini S, et al. Effects of therapy with aminaftone on chronic venous and lymphatic stasis. [in Italian. Minerva Cardioangiol. 1989;37:251–4. PubMed De Anna D, Mari F, Intini S, et al. Effects of therapy with aminaftone on chronic venous and lymphatic stasis. [in Italian. Minerva Cardioangiol. 1989;37:251–4. PubMed
61.
Zurück zum Zitat Belczak SQ, Sincos IR, Campos W, et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014;29:454–60. CrossRefPubMed Belczak SQ, Sincos IR, Campos W, et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014;29:454–60. CrossRefPubMed
Metadaten
Titel
Medikamentöse Behandlung chronischer Venenerkrankungen
verfasst von
Miloš D. Pavlović
Publikationsdatum
01.06.2016
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 9-10/2016
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0480-z